151 related articles for article (PubMed ID: 26072308)
1. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.
Brhlikova P; Harper I; Subedi M; Bhattarai S; Rawal N; Pollock AM
Global Health; 2015 Jun; 11():25. PubMed ID: 26072308
[TBL] [Abstract][Full Text] [Related]
2. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
Tauqeer F; Myhr K; Gopinathan U
Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
[TBL] [Abstract][Full Text] [Related]
3. Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.
Anyakora C; Ekwunife O; Alozie F; Esuga M; Ukwuru J; Onya S; Nwokike J
BMC Health Serv Res; 2017 Sep; 17(1):665. PubMed ID: 28923044
[TBL] [Abstract][Full Text] [Related]
4. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
5. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
Geyer ARC; Sousa VD; Silveira D
PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
[TBL] [Abstract][Full Text] [Related]
6. Good manufacturing practice: the role of local manufacturers and competent authorities.
Tomić S; Filipović Sučić A; Ilić Martinac A
Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
[TBL] [Abstract][Full Text] [Related]
7. Registration and local production of essential medicines in Uganda.
Brhlikova P; Maigetter K; Murison J; Agaba AG; Tusiimire J; Pollock AM
J Pharm Policy Pract; 2020; 13():31. PubMed ID: 32793355
[TBL] [Abstract][Full Text] [Related]
8. The make or buy debate: considering the limitations of domestic production in Tanzania.
Wilson KR; Kohler JC; Ovtcharenko N
Global Health; 2012 Jun; 8():20. PubMed ID: 22747578
[TBL] [Abstract][Full Text] [Related]
9. Reaching international GMP standards for vaccine production: challenges for developing countries.
Milstien J; Costa A; Jadhav S; Dhere R
Expert Rev Vaccines; 2009 May; 8(5):559-66. PubMed ID: 19397413
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical good manufacturing practice: Leuplin
Wada M; Ozaki A; Miyachi T; Tanimoto T; Crump A
Invest New Drugs; 2021 Aug; 39(4):1167-1169. PubMed ID: 33559805
[TBL] [Abstract][Full Text] [Related]
11. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
12. Characteristics, risk management and GMP standards of pharmaceutical companies in China.
Chen H; Qin L; Jiang C; Qin M; Sun Y; Luo J
Front Public Health; 2023; 11():1103555. PubMed ID: 36969675
[TBL] [Abstract][Full Text] [Related]
13. Medicines reclassification from a pharmaceutical industry perspective: An international qualitative study.
Gauld NJ; Kelly FS; Emmerton LM; Kurosawa N; Bryant LJM; Buetow SA
Res Social Adm Pharm; 2019 Apr; 15(4):387-394. PubMed ID: 30917892
[TBL] [Abstract][Full Text] [Related]
14. Drug quality in South Africa: perceptions of key players involved in medicines distribution.
Patel A; Norris P; Gauld R; Rades T
Int J Health Care Qual Assur; 2009; 22(5):547-60. PubMed ID: 19725374
[TBL] [Abstract][Full Text] [Related]
15. Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa.
Narsai K; Williams A; Mantel-Teeuwisse AK
South Med Rev; 2012 Jul; 5(1):31-7. PubMed ID: 23093897
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years.
Um SI; Sohn UD; Jung SY; You SH; Kim C; Lee S; Lee H
Health Res Policy Syst; 2022 Jan; 20(1):4. PubMed ID: 34991612
[TBL] [Abstract][Full Text] [Related]
17. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
Coghlan R; Stephens P; Mwale B; Siyanga M
Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
[TBL] [Abstract][Full Text] [Related]
18. Local production of pharmaceuticals in Africa and access to essential medicines: 'urban bias' in access to imported medicines in Tanzania and its policy implications.
Mujinja PG; Mackintosh M; Justin-Temu M; Wuyts M
Global Health; 2014 Mar; 10():12. PubMed ID: 24612518
[TBL] [Abstract][Full Text] [Related]
19. On a national drug policy for Bangladesh.
Islam N
Trop Doct; 1984 Jan; 14(1):3-7. PubMed ID: 6729960
[TBL] [Abstract][Full Text] [Related]
20. Implications of national tax policy on local pharmaceutical production in a southwestern state nigeria - qualitative research for the intersection of national pharmaceutical policy on health systems development.
Obembe TA; Adenipekun AB; Morakinyo OM; Odebunmi KO
BMC Health Serv Res; 2022 Feb; 22(1):264. PubMed ID: 35220971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
